OKYO Pharma LtdLSE: OKYO

OKYO Pharma to Present at the Stifel 2026 Hea...

· Issued by OKYO Pharma Ltd via GlobeNewswire

Summary by 6ix AI

OKYO Pharma Limited, a clinical-stage drug developer working on treatments for neuropathic corneal pain (nerve-related eye pain) and front-of-the-eye diseases, will take part in the Stifel 2026 Healthcare Conference, held November 10–12, 2026 at the Lotte New York Palace Hotel in New York.

Key details

  • Chief Executive Officer Robert J. Dempsey is scheduled to present at 9:20 a.m. ET on Thursday, November 12, 2026.
  • OKYO leadership will be available for one-on-one investor meetings throughout the conference, arranged through Stifel representatives.
  • A live webcast of the presentation will be available, and it will be archived for 90 days afterward in the investor section of the OKYO Pharma website.

6ix AI wrote this summary from the release below and checked it against the release.

LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the Stifel 2026 Healthcare Conference November 10–12, 2026.

Robert J. Dempsey, Chief Executive Officer, is scheduled to present at 9:20 a.m. ET on Thursday, November 12, 2026, at the Stifel 2026 Healthcare Conference to be held at the Lotte New York Palace Hotel, New York, NY. In addition to presenting, OKYO Leadership will be available for one-on-one investor meetings throughout the conference. Investors interested in arranging a meeting should contact their Stifel representative.

A live webcast of the presentation at the Stifel 2026 Healthcare Conference will be available at Stifel Live Webcast. Following the conference, the webcast will be archived for 90 days and available on the OKYO Events & Presentation section of the Investor section of the OKYO Pharma website.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. Lead candidate, urcosimod for neuropathic corneal pain (NCP), recently announced first patients enrolled in Phase 3 NEPTUNE trial. For more information, please visit www.okyopharma.com and follow us on LinkedIn.

Investor inquiries or meeting requests:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: ir@okyopharma.com

OKYO Pharma Ltd on 6ix

Earlier from OKYO Pharma

Later from OKYO Pharma

All OKYO Pharma news releases